Vertex’s Nicola Massey: the pharmaphorum podcastIn the latest episode of the podcast Dominic Tyer speaks with Nicola Massey, who’s Vertex’s senior country manager Share XVertex’s Nicola Massey: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/vertex-senior-country-manager-nicola-massey/
Nobel winner Charpentier’s CRISPR Therapeutics gets $900m in reworked Vertex dealCRISPR Therapeutics is to receive a hefty $900m payment from Vertex after the companies amended a collaboration to Share XNobel winner Charpentier’s CRISPR Therapeutics gets $900m in reworked Vertex dealhttps://pharmaphorum.com/news/nobel-winner-charpentiers-crispr-therapeutics-gets-900m-in-reworked-vertex-deal/
After Celgene deal, BMS shoots up pharma market cap rankingsBristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies Share XAfter Celgene deal, BMS shoots up pharma market cap rankingshttps://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/
COVID-19 could cause surge in virtual trials, says Vertex expertThe COVID-19 crisis is causing a surge in interest in ‘virtual trials’ where the bulk of the data Share XCOVID-19 could cause surge in virtual trials, says Vertex experthttps://pharmaphorum.com/news/covid-19-could-cause-surge-in-virtual-trials-says-vertex-expert/
Shares in Vertex jump on overnight success of CF triple therapyShares in US pharma Vertex were up sharply in premarket trading after its newly-launched cystic fibrosis triple therapy attained blockbuster status Share XShares in Vertex jump on overnight success of CF triple therapyhttps://pharmaphorum.com/news/shares-in-vertex-jump-on-overnight-success-of-cf-triple-therapy/
The 4 biggest pharma market access stories of 2019What events have defined the market access landscape in 2019, and what trends will shape 2020? We dive Share XThe 4 biggest pharma market access stories of 2019https://pharmaphorum.com/views-analysis-market-access/the-4-biggest-pharma-market-access-stories-of-2019/
After four-year wait, patients in England finally get Vertex’s cystic fibrosis drugsNHS England has signed an agreement with US pharma Vertex covering all the company’s licensed cystic fibrosis medicines, Share XAfter four-year wait, patients in England finally get Vertex’s cystic fibrosis drugshttps://pharmaphorum.com/news/breaking-news-nhs-signs-agreement-with-vertex-covering-all-cystic-fibrosis-drugs/
Vertex looks beyond cystic fibrosis with $950m Semma buyVertex Pharma is all-but synonymous with cystic fibrosis (CF) treatment but wants to diversify into new areas, including Share XVertex looks beyond cystic fibrosis with $950m Semma buyhttps://pharmaphorum.com/news/vertex-looks-beyond-cystic-fibrosis-with-950m-semma-buy/
Scotland’s cost regulator rejects Vertex cystic fibrosis drugsScotland’s cost-effectiveness body has rejected regular NHS funding for Vertex’s cystic fibrosis drugs Orkambi and Symkevi because of Share XScotland’s cost regulator rejects Vertex cystic fibrosis drugshttps://pharmaphorum.com/news/scotlands-cost-regulator-rejects-vertex-cystic-fibrosis-drugs/
